Genomic Health (GHDX) 31.12 $GHDX
Genomic Health: 2014 Financial Results Predict Strong 2015
Avner Denicoff - at Seeking Alpha - Thu Feb 12, 11:59AM CST
GHDX: 31.12 (+0.28)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 100.76 (+1.98), OPHT: 51.11 (+0.12), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
Genomic Health net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:17AM CST
GHDX: 31.12 (+0.28)
Genomic Health, Inc. on the Road to Profitability
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 11:59PM CST
If you just look at test volume, Genomic Health had a solid 2014, with a year-over-year increase of 12%. That's not hyper-growth, but double-digit growth is nothing to sneeze at. Unfortunately, the revenue line wasn't nearly as impressive,...
GHDX: 31.12 (+0.28)
Genomic Health's (GHDX) CEO Kim Popovits on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 8:49PM CST
GHDX: 31.12 (+0.28)
Genomic Health reports 4Q loss
Automated Insights - Tue Feb 10, 4:33PM CST
REDWOOD CITY, Calif. (AP) _ Genomic Health Inc. (GHDX) on Tuesday reported a loss of $6.3 million in its fourth quarter.
GHDX: 31.12 (+0.28)
Genomic Health (GHDX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
GHDX: 31.12 (+0.28)
Genomic Health beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:08PM CST
GHDX: 31.12 (+0.28)
Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook
PR Newswire - Tue Feb 10, 3:02PM CST
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2014.
GHDX: 31.12 (+0.28)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Following NICE's Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX® Breast Cancer Test
PR Newswire - Thu Feb 05, 6:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) announced today that, as of April 1, 2015, the Oncotype DX® test will be available to eligible breast cancer patients through the National Health Service (NHS) in England as the only multi-gene breast cancer test recommended by the National Institute for Health and Care Excellence (NICE) for use as an option to assist in chemotherapy treatment decision-making.
GHDX: 31.12 (+0.28)
Inivata Limited Announces New Board Member Patrick Terry
PR Newswire Europe - Thu Feb 05, 3:01AM CST
CAMBRIDGE, England, February 5, 2015 /PRNewswire/ --
GHDX: 31.12 (+0.28)
Genomic Health to Announce Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on Tuesday, February 10, 2015
PR Newswire - Tue Feb 03, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 10 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2014 financial results. The call and webcast will follow the release of the fourth quarter and year-end financial results after market close.
GHDX: 31.12 (+0.28)
Should You Buy Genomic Health (GHDX) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:03AM CST
Genomic Health is seeing favorable earnings estimate revision activity as of late and may be poised to beat at earnings season
GHDX: 31.12 (+0.28)
Genomic Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 05, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Chairman, Chief Executive Officer and President, will present at the 33rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 12 at 8:30 am Pacific Time (PT).
JPM: 59.67 (+0.10), GHDX: 31.12 (+0.28)
Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:50PM CST
Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of future tests.
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02), GHDX: 31.12 (+0.28)
Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer
PR Newswire - Thu Dec 18, 7:00AM CST
Claritas Genomics today announced the appointment of Patrick F. Terry to the role of Chief Commercial Officer. Mr. Terry, Chairman, Gray Group Ventures Ltd., and a founder of Genomic Health, Inc. [NASDAQ: GHDX], has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery. Mr. Terry will build Claritas's commercial organization to expand the company's reach to pediatric hospitals and patients and ensure that the Claritas services also meet the needs of payers. He will report to Claritas's President and Chief Executive Officer Patrice Milos, Ph.D.
GHDX: 31.12 (+0.28)
Genomic Health's Oncotype DX Positive in Multiple Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 3:50PM CST
Developer of genomic-based clinical laboratory services, Genomic Health Inc. (GHDX) recently announced positive feedback from the clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS.
MYGN: 34.03 (+0.40), HOLX: 30.46 (+0.21), GHDX: 31.12 (+0.28), NVS: 102.20 (-0.17)
Genomic Health's Breast Cancer Test Yields Positive Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 1:30PM CST
Oncotype DX breast cancer test ??? as Genomic Health's (GHDX) first product ??? has been an important contributor to U.S. invasive breast cancer business revenues since its launch in 2004.
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 15.26 (-0.14), HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
Genomic Health: 2014 Financial Results Predict Strong 2015
Avner Denicoff - at Seeking Alpha - Thu Feb 12, 11:59AM CST
GHDX: 31.12 (+0.28)
Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:06AM CST
Genomic Health (GHDX) delivered mixed financial numbers in fourth-quarter 2014 with bottom-line beat but revenue miss.
BMRN: 100.76 (+1.98), OPHT: 51.11 (+0.12), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
Genomic Health net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:17AM CST
GHDX: 31.12 (+0.28)
Genomic Health, Inc. on the Road to Profitability
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 11:59PM CST
If you just look at test volume, Genomic Health had a solid 2014, with a year-over-year increase of 12%. That's not hyper-growth, but double-digit growth is nothing to sneeze at. Unfortunately, the revenue line wasn't nearly as impressive,...
GHDX: 31.12 (+0.28)
Genomic Health's (GHDX) CEO Kim Popovits on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 8:49PM CST
GHDX: 31.12 (+0.28)
Genomic Health reports 4Q loss
Automated Insights - Tue Feb 10, 4:33PM CST
REDWOOD CITY, Calif. (AP) _ Genomic Health Inc. (GHDX) on Tuesday reported a loss of $6.3 million in its fourth quarter.
GHDX: 31.12 (+0.28)
Genomic Health (GHDX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 3:25PM CST
GHDX: 31.12 (+0.28)
Genomic Health beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:08PM CST
GHDX: 31.12 (+0.28)
Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook
PR Newswire - Tue Feb 10, 3:02PM CST
Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2014.
GHDX: 31.12 (+0.28)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:35PM CST
SGMO: 15.40 (+0.14), USNA: 101.37 (+0.53), RLOC: 3.58 (+0.42), ATEN: 4.14 (-0.09), VSAT: 62.71 (+0.53), RPXC: 13.94 (+0.42), TRMB: 26.86 (-0.40), KGC: 2.81 (-0.17), WSH: 47.83 (-0.55), TSRA: 39.27 (-0.05), FTI: 41.05 (+1.26), ACGL: 59.95 (+0.36), LOCK: 14.10 (-0.19), CERN: 70.98 (+1.15), CAP: 24.72 (-0.61), JIVE: 5.34 (+0.02), WU: 19.02 (+0.71), AKAM: 68.77 (+1.18), SKT: 36.80 (-0.21), NCR: 28.71 (+0.21), FRT: 143.96 (-0.58), SCI: 24.76 (+0.02), ELON: 1.16 (-0.01), GNW: 8.67 (+0.17), RKUS: 10.53 (-0.12), GHDX: 31.12 (+0.28), BLKB: 44.45 (+0.50), PXD: 157.85 (+9.71), SGEN: 31.57 (+0.36), OHI: 40.61 (-0.06), THOR: 40.01 (+0.54), MKTO: 28.24 (+0.20), CRL: 73.61 (-0.33), TMH: 59.69 (-0.19), ANDE: 45.11 (+0.71), XOOM: 15.77 (+0.64), HIW: 46.66 (-0.68), PAYC: 32.37 (-0.71)
Following NICE's Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX® Breast Cancer Test
PR Newswire - Thu Feb 05, 6:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) announced today that, as of April 1, 2015, the Oncotype DX® test will be available to eligible breast cancer patients through the National Health Service (NHS) in England as the only multi-gene breast cancer test recommended by the National Institute for Health and Care Excellence (NICE) for use as an option to assist in chemotherapy treatment decision-making.
GHDX: 31.12 (+0.28)
Inivata Limited Announces New Board Member Patrick Terry
PR Newswire Europe - Thu Feb 05, 3:01AM CST
CAMBRIDGE, England, February 5, 2015 /PRNewswire/ --
GHDX: 31.12 (+0.28)
Genomic Health to Announce Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on Tuesday, February 10, 2015
PR Newswire - Tue Feb 03, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 10 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2014 financial results. The call and webcast will follow the release of the fourth quarter and year-end financial results after market close.
GHDX: 31.12 (+0.28)
Should You Buy Genomic Health (GHDX) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:03AM CST
Genomic Health is seeing favorable earnings estimate revision activity as of late and may be poised to beat at earnings season
GHDX: 31.12 (+0.28)
Genomic Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 05, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Chairman, Chief Executive Officer and President, will present at the 33rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 12 at 8:30 am Pacific Time (PT).
JPM: 59.67 (+0.10), GHDX: 31.12 (+0.28)
Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:50PM CST
Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of future tests.
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02), GHDX: 31.12 (+0.28)
Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer
PR Newswire - Thu Dec 18, 7:00AM CST
Claritas Genomics today announced the appointment of Patrick F. Terry to the role of Chief Commercial Officer. Mr. Terry, Chairman, Gray Group Ventures Ltd., and a founder of Genomic Health, Inc. [NASDAQ: GHDX], has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery. Mr. Terry will build Claritas's commercial organization to expand the company's reach to pediatric hospitals and patients and ensure that the Claritas services also meet the needs of payers. He will report to Claritas's President and Chief Executive Officer Patrice Milos, Ph.D.
GHDX: 31.12 (+0.28)
Genomic Health's Oncotype DX Positive in Multiple Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 3:50PM CST
Developer of genomic-based clinical laboratory services, Genomic Health Inc. (GHDX) recently announced positive feedback from the clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS.
MYGN: 34.03 (+0.40), HOLX: 30.46 (+0.21), GHDX: 31.12 (+0.28), NVS: 102.20 (-0.17)
Genomic Health's Breast Cancer Test Yields Positive Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 1:30PM CST
Oncotype DX breast cancer test ??? as Genomic Health's (GHDX) first product ??? has been an important contributor to U.S. invasive breast cancer business revenues since its launch in 2004.
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), GHDX: 31.12 (+0.28), AFFX: 11.45 (+0.02)
United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 15.26 (-0.14), HH: 0.54 (+0.03), BRLI: 34.63 (+0.06), NEO: 4.10 (unch), DGX: 71.68 (+0.03), LH: 116.90 (+0.06), GHDX: 31.12 (+0.28)
